LEADER 10940nam 2200505 450 001 9910637725903321 005 20230422071644.0 010 $a981-19-4800-3 035 $a(MiAaPQ)EBC7165664 035 $a(Au-PeEL)EBL7165664 035 $a(CKB)25913870600041 035 $a(PPN)267816332 035 $a(EXLCZ)9925913870600041 100 $a20230422d2022 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aRole of microorganisms in pathogenesis and management of autoimmune diseases$hVolume II$iKidney, central nervous system, eye, blood, blood vessels and bowel /$fMitesh Kumar Dwivedi [and three others], editors 210 1$aSingapore :$cSpringer,$d[2022] 210 4$d©2022 215 $a1 online resource (538 pages) 311 08$aPrint version: Dwivedi, Mitesh Kumar Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases Singapore : Springer,c2023 9789811947995 327 $aIntro -- Foreword -- Preface -- Contents -- Editors and Contributors -- Part I: Human Microbiome, Vaccines and Autoimmunity -- 1: Autoimmunity and Microbiome -- 1.1 Introduction -- 1.2 Microbiota and Immune System Interaction -- 1.3 Microbiota and Autoimmunity -- 1.4 Mechanisms of Autoimmunity Induced by Microbiota -- 1.4.1 Microbiome Translocation -- 1.4.2 Molecular Mimicry -- 1.4.3 Dysregulated Immune Response -- 1.4.3.1 Secretion of Immunosuppressive Cytokines -- 1.4.3.2 Cytolysis -- 1.4.3.3 Metabolic Disruption -- 1.4.3.4 Suppression of DC Maturation and Function -- 1.5 Conclusion -- References -- 2: The Vaccines Induced Autoimmunity -- 2.1 Introduction -- 2.2 Vaccines -- 2.2.1 How Do Vaccines Work? -- 2.2.2 Types of Vaccines -- 2.2.2.1 Live Attenuated Vaccine -- 2.2.2.2 Inactivated Vaccine -- 2.2.2.3 Subunit and Conjugate Vaccines -- 2.2.2.4 Virus Like Particles -- 2.2.2.5 Viral Vector Vaccines -- 2.2.2.6 Nucleic Acid Vaccine -- 2.2.2.7 Toxoids -- 2.3 Autoimmune Diseases -- 2.3.1 Types of Autoimmune Disease -- 2.3.1.1 Systemic Autoimmune Disease -- 2.3.1.1.1 Rheumatoid Arthritis (RA) -- 2.3.1.1.2 Systemic Lupus Erythematosus -- 2.3.1.1.3 Multiple Sclerosis -- 2.3.1.1.4 Ankylosing Spondylitis -- 2.3.1.1.5 Scleroderma -- 2.3.1.1.6 Sjogren´s Syndrome -- 2.3.1.2 Organ-Specific Autoimmune Diseases -- 2.3.1.2.1 Type-1 Diabetes Mellitus (T1DM) -- 2.3.1.2.2 Hashimoto´s Thyroiditis -- 2.3.1.2.3 Vitiligo -- 2.3.1.2.4 Graves´ Disease -- 2.3.1.2.5 Autoimmune Anemia -- 2.3.1.2.6 Goodpasture´s Syndrome -- 2.3.1.2.7 Myasthenia Gravis -- 2.4 Mechanism of Vaccine Triggered Autoimmunity -- 2.4.1 Adjuvants -- 2.4.2 Molecular Mimicry -- 2.4.3 mRNA-Based Vaccines: a Trigger to Autoimmunity -- 2.4.4 Other Mechanisms -- 2.5 Vaccines Reported for Development of Autoimmunity -- 2.5.1 Hepatitis B Vaccines -- 2.5.2 Measles, Mumps, and Rubella (MMR) Vaccines. 327 $a2.5.3 Influenza Vaccine -- 2.5.4 Human Papilloma Virus (HPV) Vaccine -- 2.5.5 SARS-CoV-2 Vaccines -- 2.5.6 Other Vaccines -- 2.6 Conclusions -- References -- 3: COVID-19 and Autoimmunity -- 3.1 Introduction -- 3.2 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) -- 3.3 Virus Infection and Autoimmunity -- 3.3.1 SARS-CoV-2 Induced Autoimmunity -- 3.3.1.1 Molecular Mimicry -- 3.3.1.2 Bystander Activation -- 3.3.1.3 Cytokine Storm -- 3.3.1.4 Autoantibodies -- 3.3.1.5 Innate Immune Mechanisms -- 3.3.1.6 Genetic Susceptibility -- 3.4 Similarities Between COVID-19 Manifestations and Autoimmunity -- 3.5 Autoimmune Complications of COVID-19 -- 3.5.1 Guillain-Barre Syndrome -- 3.5.2 Immune Thrombocytopenic Purpura -- 3.5.3 Kawasaki Disease -- 3.5.4 Autoimmune Thyroid Diseases -- 3.5.5 Rheumatoid Arthritis -- 3.5.6 Systemic Lupus Erythematosus -- 3.5.7 Type 1 Diabetes -- 3.5.8 Vitiligo -- 3.5.9 Alopecia areata -- 3.5.10 Cold Agglutinin Syndrome (CAS) -- 3.5.11 Antiphospholipid Syndrome -- 3.6 Autoimmune Disease: A Risk Factor for Severe COVID-19? -- 3.7 Conclusions -- References -- 4: The Protective Discourse Between Infections and Autoimmunity -- 4.1 Introduction -- 4.2 Autoimmune Diseases -- 4.3 Proposed Mechanisms for Protective Effect of Infections on Autoimmune Diseases -- 4.3.1 Antigenic Competition -- 4.3.2 Innate Immune Mechanisms -- 4.3.3 Infections Induced Immunoregulation -- 4.4 Epidemiological Evidence for the Protective Role of Infections in Human Autoimmune Diseases -- 4.5 Animal Model Studies for Exploring the Protective Effects of Infections on Autoimmune Diseases -- 4.5.1 Type 1 Diabetes Mellitus -- 4.5.2 Rheumatoid Arthritis -- 4.5.3 Multiple Sclerosis -- 4.5.4 Inflammatory Bowel Disease (IBD) -- 4.6 Conclusions -- References. 327 $aPart II: Microorganisms in Pathogenesis and Management of Autoimmune Kidney Diseases and Adrenal Insufficiency -- 5: Microorganisms in Pathogenesis and Management of IgA Vasculitis and IgA Nephropathy -- 5.1 Introduction -- 5.2 Role of Microorganisms in the Pathogenesis of IgA Vasculitis -- 5.2.1 Bacteria -- 5.2.2 Viruses -- 5.2.2.1 SARS-CoV-2 -- 5.3 Role of Gut Microbiota in IgA Vasculitis -- 5.4 Role of Microorganisms in IgA Nephropathy -- 5.5 Therapeutic Aspects of Gut Microbiota in IgA Nephropathy -- 5.5.1 Modulation of Gut Microbiota -- 5.5.2 Suppression of Excessive Mucosal Immune Responses -- 5.6 Conclusions -- References -- 6: Microorganisms in Pathogenesis and Management of Immune-Mediated Glomerulopathies -- 6.1 Introduction -- 6.2 Glomerulopathies -- 6.2.1 Glomerulopathies Associated with Bacterial Infections -- 6.2.2 Glomerulopathies Associated with Viral Infections -- 6.2.2.1 COVID-19 and Immune-Mediated Glomerulopathies -- 6.3 Immune-Mediated Nephropathies -- 6.4 Glomerulonephritis Caused by Immune Complex Deposits -- 6.5 Glomerulopathies and Gut Microflora -- 6.6 Management of Glomerulopathies -- 6.7 Conclusions -- References -- 7: Microorganisms in Pathogenesis and Management of Autoimmune Addison´s Disease (AAD) -- 7.1 Introduction -- 7.2 Role of Microorganisms in the Pathogenesis of Autoimmune Addison´s Disease -- 7.2.1 Bacteria -- 7.2.2 Viruses -- 7.2.2.1 SARS-CoV-2 -- 7.3 Role of Gut Microbiota in Autoimmune Addison´s Disease -- 7.4 Role of Probiotics in Autoimmune Addison´s Disease -- 7.5 Conclusion -- References -- Part III: Microorganisms in Pathogenesis and Management of Central Nervous System (CNS) Demyelinating Autoimmune Diseases -- 8: Microorganisms in Pathogenesis and Management of Multiple Sclerosis (MS) -- 8.1 Introduction -- 8.2 Microbiota -- 8.3 Multiple Sclerosis and Gut Microbiota. 327 $a8.4 Multiple Sclerosis, Microbiota, and the Immune System -- 8.4.1 Smad7 Protein -- 8.5 Viruses and Multiple Sclerosis -- 8.5.1 Epstein-Barr Virus -- 8.5.2 Human Herpesvirus 6 -- 8.5.3 Human Endogenous Retroviruses -- 8.5.4 Measles, Rubella, and Varicella-Zoster Viruses -- 8.6 Probiotics and Multiple Sclerosis -- 8.7 Conclusion -- References -- 9: Microorganisms in Pathogenesis and Management of Guillain-Barré Syndrome (GBS) -- 9.1 Introduction -- 9.2 Microorganisms in the Pathogenesis of Guillain-Barré Syndrome -- 9.2.1 Bacterial Infections -- 9.2.2 Viral Infections -- 9.2.2.1 Link Between SARS-CoV-2 and Guillain-Barré Syndrome -- 9.2.3 Protozoan Infections -- 9.3 Vaccine-Induced Guillain-Barré Syndrome -- 9.4 Role of Gut Microbiota in Guillain-Barré Syndrome -- 9.5 Management of Guillain-Barré Syndrome -- 9.5.1 Immunotherapy for Guillain-Barré Syndrome -- 9.5.1.1 Plasma Exchange -- 9.5.1.2 Intravenous Immunoglobulin -- 9.5.1.3 Monoclonal Antibody -- 9.5.2 Role of Probiotics and Prebiotics in Guillain-Barré Syndrome -- 9.6 Future Perspectives -- 9.7 Conclusions -- References -- 10: Microorganisms in Pathogenesis and Management of Neuromyelitis Optica Spectrum Disorder -- 10.1 Introduction -- 10.2 Pathogenesis -- 10.3 Risk Factors -- 10.4 The Role of Microorganisms in the Pathogenesis of Neuromyelitis Optica -- 10.4.1 Bacteria -- 10.4.1.1 Mycobacterium tuberculosis -- 10.4.1.2 Gut Microbiome -- 10.4.1.3 Helicobacter pylori -- 10.4.2 Viruses -- 10.4.2.1 Epstein-Barr Virus (EBV) -- 10.4.2.2 SARS-CoV-2 -- 10.4.2.3 Varicella Zoster Virus (VZV) -- 10.4.2.4 Dengue Virus -- 10.4.2.5 Cytomegalovirus (CMV) -- 10.4.2.6 Herpes Simplex Virus 2 (HSV2) -- 10.4.2.7 Zika -- 10.5 Diagnostic of NMOSD -- 10.6 The Role of Infections in Causing an Attack in Patients with NMOSD -- 10.7 Infection of NMOSD Patients with Infectious Diseases and Its Complications. 327 $a10.8 Management of NMOSD Through Microorganisms -- 10.9 Conclusion -- References -- 11: Microorganisms in Pathogenesis and Management of Acute Disseminated Encephalomyelitis (ADEM) -- 11.1 Introduction -- 11.2 Mechanisms of Microorganism-Induced Autoimmunity -- 11.3 Evidence in Illnesses -- 11.3.1 Demyelinating Disease: Guillain-Barre Syndrome (GBS) -- 11.3.2 Acute Disseminated Encephalomyelitis (ADEM) -- 11.3.3 Definitions -- 11.3.4 Epidemiology -- 11.4 ADEM and Microbial Link -- 11.4.1 Viral Causes -- 11.4.2 SARS-CoV-2 and Other Coronaviruses -- 11.4.3 Bacterial Causes -- 11.4.4 Parasitic Causes -- 11.4.5 Vaccination-Induced ADEM -- 11.4.6 Other Causes of ADEM -- 11.5 Pathogenesis of ADEM -- 11.6 ADEM and Gut Microbiota -- 11.7 Pathological Findings of ADEM -- 11.8 Clinical Features of ADEM -- 11.9 Diagnosis of ADEM -- 11.9.1 Neuroimaging -- 11.9.2 CSF Analysis -- 11.9.3 CNS Angiography -- 11.9.4 EEG -- 11.9.5 Serological Tests -- 11.9.6 Multiphasic Disseminated Encephalomyelitis (MDEM) -- 11.9.7 Differential Diagnosis -- 11.10 Treatment of ADEM -- 11.10.1 Probiotics as a Potential Therapeutic Option -- 11.10.2 Prognosis -- 11.10.3 Sequelae -- 11.10.4 Prevention -- 11.11 Conclusion -- References -- Part IV: Microorganisms in Pathogenesis and Management of Inflammatory Bowel Diseases (IBDs) -- 12: Microorganisms in Pathogenesis and Management of Ulcerative Colitis (UC) -- 12.1 Introduction -- 12.2 Role of Microorganism in the Pathophysiology of Ulcerative Colitis -- 12.3 Role of Microorganisms in the Management of Ulcerative Colitis -- 12.4 Conclusion -- References -- 13: Microorganisms in the Pathogenesis and Management of Crohn´s Disease (CD) -- 13.1 Introduction -- 13.2 Role of Gut Microbiota in the Pathogenesis of Crohn´s Disease -- 13.2.1 Microbe-Host Interactions in Crohn´s Disease -- 13.2.2 Intestinal Permeability. 327 $a13.3 Microorganisms in the Pathogenesis of Crohn´s Disease. 606 $aAutoimmune diseases 606 $aAutoimmune diseases$xTreatment 606 $aMicrobial ecology 615 0$aAutoimmune diseases. 615 0$aAutoimmune diseases$xTreatment. 615 0$aMicrobial ecology. 676 $a616.978 702 $aDwivedi$b Mitesh Kumar 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910637725903321 996 $aRole of microorganisms in pathogenesis and management of autoimmune diseases$93089460 997 $aUNINA LEADER 02589nam 2200565 a 450 001 9910789603803321 005 20230725031001.0 010 $a1-283-05068-4 010 $a9786613050687 010 $a90-485-1442-8 035 $a(CKB)2670000000082278 035 $a(EBL)675618 035 $a(OCoLC)713010184 035 $a(SSID)ssj0000518749 035 $a(PQKBManifestationID)11318199 035 $a(PQKBTitleCode)TC0000518749 035 $a(PQKBWorkID)10494831 035 $a(PQKB)10158284 035 $a(MiAaPQ)EBC675618 035 $a(EXLCZ)992670000000082278 100 $a20110418d2011 uy s 101 0 $adut 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 13$aDe kloof overbrugd?$b[electronic resource] $erede uitgesproken bij de aanvaarding van het ambt van hoogleraar Acute Kindergeneeskunde & Intensive Care aan de Universiteit van Amsterdam op donderdag 2 december 2010 /$fdoor Bert Bos 210 $aAmsterdam $cVossiuspers UvA$d2011 215 $a1 online resource (22 p.) 225 1 $aOratiereeks ;$v391 300 $aDescription based upon print version of record. 311 $a90-5629-677-9 320 $aIncludes bibliographical references. 327 $aDe kloof overbrugd?; Waarvoor is kinder-intensive care eigenlijk bedoeld?; Mortaliteit versus morbiditeit; Ouders, verpleegkundigen en artsen; Onze organisatie en het kind; De toekomst; Dankwoord; Referenties 330 $aIntensive care voor kinderen is een jong specialisme binnen de kindergeneeskunde. Het specialisme richt zich op de behandeling van ernstig zieke kinderen: van ernstig zieke (voldragen) pasgeborenen tot adolescenten. In ons land zijn de intensive care-afdelingen voor kinderen exclusief verbonden aan de Universitair Medische Centra en jaarlijks worden bijna 5000 kinderen op deze afdelingen opgenomen. Het doel van de behandeling is niet alleen het verminderen van sterfte maar ook het behoud van kwaliteitvan leven en dus het voorko?men van restschade door ziekte en de meestal agressieve behandeling 410 0$aOratiereeks ;$v391. 606 $aPediatric intensive care 606 $aCritical care medicine 615 0$aPediatric intensive care. 615 0$aCritical care medicine. 676 $a618.92/01 700 $aBos$b Bert$01512051 712 02$aUniversiteit van Amsterdam.$bFaculteit der Geneeskunde. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910789603803321 996 $aDe kloof overbrugd$93745707 997 $aUNINA